![]() |
||||||||||||
China sees increased international competitiveness in intellectual property
a senior official with the administration, cited three indicators, one being the trade of China's IP royalties, which was close to 280 billion yuan (about $44 billion) in the first three quarters of this year. The export volume of IP royalties, in particular, increased over 27 percent year on year. The second one is the Global Innovation Index by the World Intellectual Property Organization, in which China climbed to 12th this year, up two notches from 14th in 2020, ranking first among the world's mid-income economies. "China has risen 23 places in the rankings since 2012. The continuous growth reflects China's decades-long commitment to investing in science, technology and education, as well as its progress in building a modern and effective IP system," Lei noted... Persistent opening-up best manifestation of China’s WTO commitment
celebrate its 20th WTO entry anniversary and promote development and deliver dividends to the world, in spite of the rising protectionism that is posing threat to the current global trade. China is a trustworthy member of the WTO, has fully and effectively fulfilled its commitments to the organization, and has earned wide recognition from the vast majority of WTO members. In its resolute efforts to reach the WTO goal of ensuring that "trade flows as smoothly, predictably and freely as possible," the country's overall tariff level has dropped to 7.4 percent from 15.3 percent in 2001, lower than the 9.8 percent the country promised when entering the WTO...
October, will last to the end of June, Zhang Zhichang, head of CNIPA's intellectual property protection department, told a news conference. Zhang said the campaign will also help ensure the Beijing 2022 Winter Olympics and Paralympics can be run smoothly. During the campaign, those who infringe patents or trademarks involving Olympic symbols will be harshly punished, he said, adding that IPR-related inspections in places that produce or sell Olympic products as well as at e-commerce giants need to be intensified... Two Chinese COVID-19 medicines receive emergency approval
medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA. Specifically, the medicines are conditionally approved for adolescents ranging from 12 to 17 years of age with a body weight greater than 40 kg. Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences have jointly developed the cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which are derived from antibodies isolated from people who have recovered from COVID-19. |